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Introduction  
Adrenal haemorrhage (AH) is a rare condition with an unknown incidence. Due to 
non-specific symptoms at presentation, it can present to many specialities (e.g. general 
Key points for clinicians regarding Adrenal Haemorrhage (AH) 
 AH should be considered in anticoagulated patients with new-onset back pain. 
 Acute AH should be managed as an acute adrenal crisis with intravenous 
hydrocortisone 
(1)
.  
 Underlying neoplastic pathology of the adrenal gland must be considered in the context 
of acute AH, interval imaging may reveal the diagnosis.  
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medicine, urology, emergency medicine etc.), clinicians require a high clinical suspicion to 
avoid missing the diagnosis.  
AH has potentially life threatening consequences and historically was often diagnosed 
at autopsy 
(2)
. AH has been reported to occur spontaneously, but is associated with additional 
predisposing factors. Those reported include anticoagulation, underlying adrenal lesion (e.g. 
metastatic disease or primary adrenal tumour), trauma, severe sepsis (e.g. Waterhouse-
Frederichson’s syndrome associated with meningococcal septicaemia), antiphospholipid 
antibody syndrome, burns, or the early postoperative period, including unrelated procedures 
(e.g. joint arthroscopy, laparotomy) 
(1–3)
. 
Clinical cases 
In Table 1 we summarise key points of three cases of AH presenting to our institution, 
demonstrating the heterogeneous presentation, management and underlying pathologies 
associated with this condition.  
Discussion 
Hypotension, shock and non-specific abdominal pain are commonly reported 
presenting features for significant AH 
(2)
. Others can include weakness, vomiting, palpable 
abdominal masses, and tenderness. Unilateral or minor AH may go undetected. Although 
reported in unilateral AH, adrenal insufficiency (AI) is more common with bilateral AH, as 
90% of the adrenal tissue must typically be destroyed before hormone deficiency is clinically 
apparent. Biochemical investigations may demonstrate hyponatraemia and hyperkalaemia but 
this is not uniform in all cases. 
AI resulting in adrenal crisis is a medical emergency and treatment should not be 
delayed in cases of high clinical suspicion. Treatment with high dose intravenous (IV) 
hydrocortisone should be commenced immediately to prevent rapid clinical deterioration and 
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shock. Ideal treatment regimen is 100 mg IV bolus of hydrocortisone, followed by a 200 mg 
infusion over 24 hours, or 50 mg boluses every 6 hours 
(1)
. IV rehydration should also be 
initiated according to clinical need. 
A recognised method for reliably diagnosing glucocorticoid deficiency is to carry out 
a short Synacthen test (Cosyntropin test), measuring serum cortisol at baseline and 30 
minutes post intramuscular or IV injection with 250 micrograms of synthetic ACTH 
(1)
. Due 
to assay inter-variability, cut off values for cortisol will depend on your local hospital assays 
derived from unselected normative data 
(4)
. Diagnostic measures should never delay treatment 
and hence in the case of strong clinical suspicion of acute adrenal insufficiency, 
hydrocortisone treatment should be initiated without awaiting laboratory results. A diagnosis 
of concurrent mineralocorticoid deficiency is made by an elevated plasma renin and low 
aldosterone levels on a paired sample. Once confirmed synthetic mineralocorticoid 
replacement should be added, once the oral hydrocortisone dose is reduced below a total 
daily dose of 50 mg (e.g. fludrocortisone 100-150 micrograms per day) 
(3)
. 
Due to the acute nature of AH, computed tomography (CT) is often the first modality 
of imaging to be performed. A diagnosis of AH may be suspected by the presence of 
enlargement and distortion of the adrenal glands, with hyperdense areas pre-contrast; pre-
adrenal fat stranding is also a recognised feature. Contrast enhanced magnetic resonance 
imaging (MRI) has higher sensitivity and specificity for identifying underlying haemorrhagic 
pathology, and may help delineate the acuteness of AH by haemoglobin breakdown products. 
(5)
. Ideally, follow-up imaging should demonstrate a reduction in the size of the bilateral 
masses. 
Whilst most cases are self-limiting, adrenalectomy or embolisation may be required in 
occasional refractory cases of AH 
(6)
. A diagnosis of AH should raise the suspicion of 
underlying overt or occult primary or secondary adrenal malignancy in patients without a 
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history of recent anticoagulation, as demonstrated in Case 3. Equally, underlying connective 
tissue disease or vasculitis should be excluded. 
AH associated AI has the potential to recover, and ongoing assessment with 9am 
cortisol and/or short Synacthen tests as per local protocols to assess adrenal reserve should be 
undertaken at appropriate intervals.  
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Table 1 
 Case 1 Case 2 Case 3 
Age, Sex 63 year old male  70 year old male 79 year old female 
Past medical 
history at time 
of diagnosis 
Thromboembolic disease 
(recently anticoagulated) 
Rheumatoid arthritis with 
interstitial lung disease 
Pulmonary embolism 
October 2015 
COPD 
Coeliac disease 
Diverticular disease. 
 Type 2 diabetes. 
Hypertension. 
Upper GI bleed. 
Congestive cardiac failure 
Medication 
Warfarin, Sulfasalazine, 
Methotrexate, Simvastatin 
Sodium Docusate, 
Ranitidine, Salbutamol & 
Tiotropium Inhaler. 
Clopidogrel, Doxazosin. 
Ramipril. Bisoprolol. 
Frusemide. Atorvastatin. 
Insulin, Calcium/Vit D, 
Dosulepin, Metformin. 
Symptoms 
Acute right flank pain. 
Night sweats with weight 
loss. 
Breathlessness; 
underwent CTPA showed 
bilateral adrenal masses. 
Further investigations 
arranged. 
Acute and severe left-
sided back pain located 
close to the spine 
Initial 
working 
diagnosis 
Possible metastatic lung 
cancer new lesion 
identified in lung. 
Pulmonary embolus Renal colic 
Imaging 
CT: bilateral adrenal 
abnormalities 
measuring   3.1 cm on 
the right and 2.6 cm on 
the left (not demonstrated 
on scan 18 months prior). 
CT with contrast: Rapid 
bilateral adrenal 
enlargement between 
October and December 
2015, density of adrenal 
gland 30HU. 
CT: 2 x 4 cm Left adrenal 
mass 2014, appearances 
consistent with AH. 
Subsequent right adrenal 
bleed on clopidogrel 2015 
Adrenal work 
up 
(Plasma renin 
normal range 
5.1-38.7) 
 
Glucocorticoid deficiency 
(morning cortisol 150 
nmol/l) 
Plasma renin: 96.7 ng/l  
Aldosterone: <30 pmol/l 
Glucocorticoid deficiency 
(SST 0 min 165, 30 min 
176 nmol/L) 
Plasma renin 122 ng/l; 
aldosterone: <30 pmol/l 
Glucocorticoid deficiency 
(SST 0 min 341nmol/l, 30 
min 414nmol/l) 
Plasma renin 174.8 ng/l 
Aldosterone 60 pmol/l 
Initial 
working 
diagnosis 
Bilateral AH with AI 
secondary to recent 
anticoagulation.  
Lung lesion requires 
further investigation. 
Bilateral AH with AI 
secondary to recent 
anticoagulation.  
AH (initially left, with 
subsequent right AH) 
Outcome 
Significant and 
progressive reduction in 
size of lesions on 6 month 
interval imaging.  
Lung lesion subsequently 
diagnosed as 
inflammatory change 
MRI: right adrenal gland 
reduced in size from 4.3 x 
2.9   cm to 3.2 x 1.9 cm. 
Left adrenal gland also 
reduced   in size from 4.3 
x 2.9 cm to 2.8 x 2.4 cm. 
Further bilateral adrenal 
enlargement on follow-up 
imaging. CT-guided 
biopsy confirmed 
metastatic hepatocellular 
carcinoma (HCC). 
Final 
diagnosis 
AI secondary to bilateral 
AH. 
AI secondary to bilateral 
AH. 
Metastatic HCC with 
bilateral adrenal 
metastases. Died 2015 
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